Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1

Interventions

Specimen Handling 80Fluorouracil 74Oxaliplatin 69Magnetic Resonance Spectroscopy 61Leucovorin 58Gemcitabine 55Bevacizumab 55Biopsy 41Capecitabine 40Irinotecan 37Cisplatin 36Nivolumab 35pembrolizumab 33Cetuximab 33durvalumab 30Paclitaxel 27130-nm albumin-bound paclitaxel 27atezolizumab 20Folfox protocol 20Radiotherapy 17Carboplatin 17dehydroftorafur 15Taxes 15Cyclophosphamide 15fludarabine 13X-Rays 13Radiation 13trastuzumab deruxtecan 12Surgical Procedures, Operative 12Albumin-Bound Paclitaxel 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
IDRX-42 × Gastrointestinal × 30 days × Clear all
NCT07218926 2026-05-27

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

GlaxoSmithKline

Phase 3 Recruiting
450 enrolled
GastrointestinalSarcoma

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡